Daptomycin

被引：77

作者：

Enoch, David A. ^{[1
]}

Bygott, Jeanine M. ^{[1
]}

Daly, Marie-Louise ^{[1
]}

Karas, J. Andreas ^{[1
]}

机构：

[1] Papworth Hosp, Hlth Protect Agcy, Clin Microbiol & Publ Hlth Lab, Cambridge CB3 8RE, England

来源：

JOURNAL OF INFECTION | 2007年 / 55卷 / 03期

关键词：

daptomycin; skin and soft tissue infection; bacteraemia and endocarditis; Gram positive infections;

D O I：

10.1016/j.jinf.2007.05.180

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

There has been a steady rise in the prevalence of resistant Gram-positive pathogens and concerns about the clinical effectiveness of glycopeptides in treating infections due to Staphylococcus aureus. Daptomycin is a novel lipopeptide antimicrobial agent with activity against Gram-positive organisms, including mufti-resistant strains. It is licensed in the USA and Europe for the treatment of complicated skin and soft tissue infections caused by Gram-positive organisms at a dose of 4 mg/kg once daily. It has also been licensed in the USA for the treatment of S. aureus bacteraemia and right-sided endocarditis at 6 mg/kg once daily. It is a safe and well-tolerated antibiotic, particularly at the current dosing regimen. Antimicrobial resistance, whilst being increasingly reported, still remains relatively rare. Further studies are required to determine the role of daptomycin for the treatment of osteomyelitis and septic arthritis, as well as its use in combination therapy. (c) 2007 The British Infection Society. Published by Elsevier Ltd. AR rights reserved.

引用

页码：205 / 213

页数：9

共 86 条

[21] Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus [J].

Fowler, Vance G., Jr. ;

Boucher, Helen W. ;

Corey, G. Ralph ;

Abrutyn, Elias ;

Karchmer, Adolf W. ;

Rupp, Mark E. ;

Levine, Donald P. ;

Chambers, Henry F. ;

Tally, Francis P. ;

Vigliani, Gloria A. ;

Cabell, Christopher H. ;

Link, Arthur Stanley ;

DeMeyer, Ignace ;

Filler, Scott G. ;

Zervos, Marcus ;

Cook, Paul ;

Parsonnet, Jeffrey ;

Bernstein, Jack M. ;

Price, Connie Savor ;

Forrest, Graeme N. ;

Faetkenheuer, Gerd ;

Gareca, Marcelo ;

Rehm, Susan J. ;

Brodt, Hans Reinhardt ;

Tice, Alan ;

Cosgrove, Sara E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (07) :653-665

[22] Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus [J].

Friedman, L ;

Alder, JD ;

Silverman, JA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (06) :2137-2145

[23] In vitro bactericidal activity of daptomycin against staphylococci [J].

Fuchs, PC ;

Barry, AL ;

Brown, SD .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (03) :467-470

[24] Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests [J].

Fuchs, PC ;

Barry, AL ;

Brown, SD .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 38 (01) :51-58

[25] Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media [J].

Fuchs, PC ;

Barry, AL ;

Brown, SD .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (04) :557-561

[26] In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. [J].

Goldstein, EJC ;

Citron, DM ;

Merriam, CV ;

Warren, YA ;

Tyrrell, KL ;

Fernandez, HT .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) :2149-2152

[27] In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria [J].

Goldstein, EJC ;

Citron, DM ;

Merriam, CV ;

Warren, Y ;

Tyrrell, K ;

Fernandez, HT .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (06) :1968-1971

[28] In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates [J].

Goldstein, EJC ;

Citron, DM ;

Merriam, CV ;

Warren, YA ;

Tyrrell, KL ;

Fernandez, HT .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) :337-341

[29] In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections [J].

Goldstein, Ellie J. C. ;

Citron, Diane M. ;

Warren, Yumi A. ;

Tyrrell, Kerin L. ;

Merriam, C. Vreni ;

Fernandez, Helen T. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (08) :2875-2879

[30]

Green Myke R, 2006, J Oncol Pharm Pract, V12, P179, DOI 10.1177/1078155206069165

← 1 2 3 4 5 6 7 8 9 →